You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Incidence of discontinuation and adverse events

From: High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

  3-MU group, No. (%) 6-MU group, No. (%) P value
Patient number 80 134  
Discontinuation 4 (5.0) 10 (7.5) NS
   Adverse event 3 (3.8) 6 (4.5) NS
   Insufficient response 1 (1.3) 1 (0.7) NS
   Laboratory abnormality 0 (0) 1 (0.7) NS
   Economic problem 0 (0) 2 (1.5) NS
Adverse event    
   Flu-like symptoms† 49 (61.3) 85 (63.4) NS
   Gastrointestinal manifestations‡ 19 (23.8) 35 (26.1) NS
   Psychological manifestations§ 34 (41.0) 74 (55.2) 0.028
   Alopecia 13 (16.3) 30 (22.4) NS
   Dermatological manifestations¶ 11 (13.8) 19 (14.2) NS
  1. Note: 3-MU group: interferon-α 3 million units thrice weekly for 24 weeks.
  2. 6-MU group: interferon-α 6 million units thrice weekly for 24 weeks.
  3. NS: not significant.
  4. † Including fatigue, headache, pyrexia, myalgia, and rigors.
  5. ‡ Including nausea, vomiting, anorexia, and diarrhea.
  6. §Including irritability, depression, and insomnia.
  7. ¶Including dermatitis, and pruritus.